Skip to content

Study · Animal study (in vivo) · mouse · 2022

1 result

Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists.

Patch RJ, Zhang R, Edavettal S, Macielag MJ, Eckardt AJ, Li J, Rives ML, Edwards W, Hinke SA, Qiu X, Jian W, Libiger O and 6 more

Show all authors

Zheng S, Jeyaseelan J, Liang Y, Rangwala SM, Leonard JN, Hornby P

European journal of medicinal chemistry4 Apr 2022Cited by 6 (Europe PMC)

PMID35436670 (opens in a new tab)DOI10.1016/j.ejmech.2022.114330 (opens in a new tab)PepBankPUB-35436670
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, pramlintide had a half-life below 0.75 h, shorter than the tested bioconjugates.

    In plain wordsIn mice, pramlintide had a shorter half-life than the tested bioconjugates.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableHalf-life
    Study

    mousen: not reported in source

    mice
    Comparator
    bioconjugates 35 and 38
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Pramlintide half-life
    < 0.75 h
    pramlintide comparator

    Source sentences

    Summary
    In contrast to pramlintide (t1/2 < 0.75 h), bioconjugates 35 and 38 have terminal half-lives of ∼2 days in mice and attain significant exposure levels that are maintained up to 7 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.